Mark Levin, co-founder of Third Rock Ventures and an industry leader with 40 years of experience will be honored with the Henri A. Termeer Innovative Leadership Award at the 2015 MassBio Annual Meeting.
Hear his remarks at the Awards Luncheon on Thursday, March 26!
During this Luncheon we will also honor the Joshua Boger Innovative School of the Year and present the MassBio Leading Impact Award.
We look forward to seeing you there!
Astrocyte Pharmaceuticals Inc. is a new drug development company dedicated to clinically proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury patients. Astrocyte Pharmaceuticals is developing a proprietary small molecule pharmaceutical agent for acute administration to patients who have suffered a TBI, concussion or stroke. This product would be administered by intravenous injection by emergency responders or a medical professional within 24 hours of injury to limit neuronal damage and cell death. Our approach at Astrocyte Pharmaceuticals differs significantly from historical neuroprotective attempts as we focus on a non-neuronal cell type, astrocytes, which are the most common cell type in the human brain and have only recently received broader attention as important cellular targets for therapeutic research. Additionally, as astrocytes are the natural caretaker cells in the brain and their activation, as our data show, enhances multiple natural healing mechanisms including protection against edema, glutamate excitotoxicity and oxidative stress. Website.
Baxter Healthcare Corporation, is developing proprietary formulation technology platform, PROMAXX at their facility in Norwood MA. The technology, based on controlled phase separation, allows the formation of microspheres that have a broad range of applications – from the formulations of proteins and peptides for pulmonary delivery to the formulation of highly concentrated suspension of monoclonal antibodies and other proteins for Subcutaneous injection. Baxter offers potential partners the opportunity to assess the feasibility of developing innovative formulations and product profiles for their molecules and if successful to manufacture clinical grade material. Website.
CRISPR Therapeutics is a biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough genome-editing technology, into transformative medicines for serious human genetic diseases. The company is uniquely positioned to translate CRISPR-Cas9 technology into human therapeutics, thanks to its multi-disciplinary team of world-renowned academics, clinicians and drug developers. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK. Website.
The Economic Development Council of Western Massachusetts (EDC) is a business created development corporation that brings the region’s public and private sector leaders together with the singular focus of expanding economic opportunity in the three counties of the Pioneer Valley: Hampden, Hampshire and Franklin. Affiliated with seven independent western Massachusetts economic and business development organizations, the EDC provides a broad array of services to prospective businesses and organizations interested in the area, as well as those already here who are expanding, helping them find funding and networking resources to stimulate business expansion. Affiliates include the Affiliated Chambers of Commerce of Greater Springfield, Inc.; Business Improvement District; Greater Springfield Convention and Visitors Bureau; Regional Technology Corporation; Springfield Business Development Corporation; Westmass Area Development Corporation and Westover Metropolitan Development Corporation. Website.
At SciSafe, we have taken a different approach to the market. We have formed a team of industry specialists that fully understand the actual process involved in specimen storage for Biological and Pharmaceutical Materials. We feel at SciSafe that the market for storage only services does not offer clients the real understanding of processes and procedures that you the client must follow. We have built these processes from the ground up within this organization. This requires us to have the most talented group of individuals in this field that have specifically worked in sample management and Cold Chain Logistics. With over 60 year’s experience, we know that we can assist you with your requirements. Website.
1) With the help of patient groups, biotechs hone in on rare diseases – BBJ, February 26, 2015
This Saturday is worldwide Rare Disease Day, the eighth such day coordinated by the European Organization for Rare Diseases to draw attention to the some 7,000 diseases which are shares by a small number of patients each — many just a few thousand — but collectively affect 350 million people globally. Fueled both by scientific advances in genetics and the support of patient organizations, the biotech industry is showing more interest than ever in developing drugs for such diseases. Besides Genzyme Corp. and Shire, scores of smaller biotechs are focusing on genetically defined conditions with small patient populations.
2) Cost concerns at center of debate over rare disease treatment – Nashoba Publishing, February 26, 2015
As drug companies pioneer new methods of treating an array of diseases, some lawmakers want to limit the out-of-pocket cost to health plan members purchasing medications while others worry that tack would cause costs to soar.
3) What 23andMe’s FDA Approval Means For The Future Of Genomics – Forbes, February 20, 2015
Last night, the Food and Drug Administration approved a test made by 23andMe, the Mountain View, Calif.-based personal genetics company, for a gene that can cause a rare disorder called Bloom Syndrome, which causes short stature and a heightened risk of cancer.
4) Cambridge firms will use gene database to make new drugs – Boston Globe, February 23, 2015
Two Cambridge life sciences companies have struck a deal to collaborate on making new cancer drugs.Foundation Medicine, which tests tumors for genetic mutations and suggests treatment plans to doctors, said it would make its genetic database available to H3 Biomedicine as part of a multi-year agreement to create and commercialize new drugs. The database, called FoundationCORE, contains genetic information on more than 35,000 samples.
5) Dicerna doubles in size and moves to West Cambridge – BBJ, February 26, 2015
With two clinical trials underway and a third set to begin later this year, Dicerna Pharmaceuticals is today moving into a new lab and office space that’s twice the size of its Watertown headquarters.
Together, as partners with our customers, we are committed to provide product development services with new and innovative ways to reduce costs and lead times, while continually maintaining the highest quality standards. Quality is a fundamental and integral part of our business. Through our People and Systems, we provide high quality products and professional services to the pharmaceutical industry. We always strive to exceed all the expectations of our customers. CuriRx Incorporation’s goal is to create new standards of care in therapeutic areas with high unmet medical needs by partnering and providing innovative solutions for drug development of pharmaceutics, biopharmaceutics, vaccines, generics and biosimilars products. Website.
Dovel Technologies implements modern and emerging technologies to deliver architecture-driven solutions that actually work. Our team creates software solutions that are low-impact and help customers communicate, access, and store mission critical information. Dovel technologists have been instrumental in the design and implementation of some of the most mission critical and innovative systems in government today including: Department of Defense Travel System, DoD OneStop, DoD Trip Cost Estimator, Food and Drug Administration Emergency Operation, FDA MARCS Recall Systems, Federal Aviation Administration System Wide Information Management System. Website.
Rubius Therapeutics is focused on developing circulating cell therapies for autoimmune and rare metabolic diseases.
MassCONNECT, the only entrepreneur mentorship program in Massachusetts that dives deep into the life sciences industry, kicked off its first cycle of 2015 with a Technology Showcase at LabCentral on February 24th. At the Showcase, the chosen entrepreneurs presented their ideas to a room of industry executives and potential mentors for early feedback.
First up to present was Yoav Golan, MD, MS of Tufts NewCo. This new company started by Golan and his colleague Abraham (Linc) Sonenshein, PhD is developing a new non-antibiotic molecular entity to prevent and treat C. Difficile, a leading cause of healthcare associated bacterial infections.
Next up was Cinzia Metallo, PhD of Biomille Technologies which has developed the first device specifically designed for facial muscle rehabilitation. Biomille’s electrodes are shaped to match the muscle anatomy of the face and enable patients affected by a vast range of facial impairments to regain their facial muscle functionality.